New Platinum-Gold Drugs for Ovarian Cancer
Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian Cancer
This research is creating new platinum-gold drugs to better treat ovarian cancer, especially for patients whose cancer has become resistant to current chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brooklyn College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11112545 on NIH RePORTER |
What this research studies
Ovarian cancer is a very serious disease, often diagnosed at advanced stages when it's harder to treat, and many patients experience their cancer returning after initial chemotherapy. Current platinum-based chemotherapy drugs, while effective at first, often lead to cancer cells becoming resistant over time and can cause difficult side effects. Our team is working to develop new platinum-gold drugs that aim to overcome this resistance and target cancer cells more effectively. These new drugs are designed to release both platinum and gold components inside cancer cells, attacking the tumor in multiple ways and potentially improving treatment outcomes.
Who could benefit from this research
Good fit: This research is focused on developing new treatments for patients with ovarian cancer, especially those whose disease has become resistant to current platinum-based chemotherapy.
Not a fit: Patients without ovarian cancer or those whose cancer responds well to existing treatments may not directly benefit from this specific drug development effort.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatment options for ovarian cancer, particularly for patients who no longer respond to standard chemotherapy.
How similar studies have performed: While platinum-based drugs are a standard treatment, this approach of combining platinum and gold in a single agent to overcome resistance is a novel strategy.
Where this research is happening
New York, United States
- Brooklyn College — New York, United States (Active)
Researchers
- Principal investigator: Contel, Maria — Brooklyn College
- Study coordinator: Contel, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.